Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/22/2019 6:04:07 PM - Followers: 79 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).



New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#2076   i read the 8k but im not sure saigai 01/22/19 06:04:07 PM
#2075   yep 20 is the new 16 saigai 01/22/19 11:48:45 AM
#2074   Looks like .20 is going to be support. soflodiver 01/18/19 10:32:29 AM
#2073   only if you spot me a few grand saigai 01/16/19 10:10:42 PM
#2072   averaging down I see. good job! You most SidVicious 01/16/19 02:29:59 PM
#2071   added 10k this morning... saigai 01/16/19 12:28:20 PM
#2067   How much is the stock up this morning? LOL SidVicious 01/16/19 09:51:46 AM
#2066   whether it holds or not - i'm betting SidVicious 01/16/19 09:37:00 AM
#2065   Is the support at .22 gonna hold?.........That’s hedge_fun 01/16/19 06:24:48 AM
#2064   How much did precipridrop close up today? SidVicious 01/15/19 11:01:45 PM
#2063   none of these deals are going to include SidVicious 01/15/19 08:42:37 PM
#2062   Makati Medical Center and their investment connections mgland 01/15/19 11:12:02 AM
#2061   PRPO Up 6%, was UP 6.5% Pre Market on instock58 01/15/19 09:35:22 AM
#2060   Good news to a degree. Would really like SidVicious 01/15/19 08:28:49 AM
#2059   PRPO NEWS: " Makati Medical Center in the instock58 01/15/19 08:07:54 AM
#2058   Multi millions traded last few days. Now that MasterKevo 01/15/19 06:18:54 AM
#2057   its good to have a trading position. saigai 01/14/19 06:59:11 PM
#2056   started buying back today at .231 and .221. PennyStockTrader2 01/14/19 04:41:20 PM
#2055   What analyst said it should be up?...... hedge_fun 01/14/19 04:03:27 PM
#2054   Bingo. A sucker is born every minute and SidVicious 01/14/19 03:48:59 PM
#2053   as far as analyst are concerned. i saigai 01/14/19 03:46:35 PM
#2052   we are heading back to the teens.. the saigai 01/14/19 03:32:44 PM
#2051   Anyone can analyze charts after-the-fact! I'll pay Dean The Great 01/14/19 02:38:51 PM
#2050   Stock going the wrong way!! Dean The Great 01/14/19 02:34:30 PM
#2049   wow!! You OBVIOSLY NEVER a Member of Clays instock58 01/14/19 12:23:14 PM
#2048   yeh, that's a bummer about RGBP being instock58 01/14/19 12:19:52 PM
#2047   ive been here a long time.. way before saigai 01/14/19 10:22:38 AM
#2046   Considering I have watched Clay's vids many times SidVicious 01/14/19 10:17:47 AM
#2045   if you clicked the link and watched the saigai 01/14/19 10:15:24 AM
#2044   yes, PRPO strong like bull this morning! The SidVicious 01/14/19 10:07:29 AM
#2043   anyway the chart is hopeful in this case saigai 01/14/19 12:44:08 AM
#2042   Keep living in dream world..NO, everyone BUT Newbies instock58 01/13/19 10:24:31 PM
#2041   still holding...long term saigai 01/13/19 05:34:57 PM
#2040   Ok, if you say so. But anyone with SidVicious 01/13/19 01:46:55 PM
#2039   PRPO I won't because Fools don't Chart. Like instock58 01/13/19 11:29:12 AM
#2036   PRPO UP Thur 43%, Up Fri 11%, Up instock58 01/12/19 02:57:51 PM
#2032   * * $PRPO Video Chart 01-11-2019 * * ClayTrader 01/11/19 05:14:00 PM
#2031   Thx for your input. I've seen lots.... hedge_fun 01/11/19 03:58:36 PM
#2030   I won't because charting is for fools. SidVicious 01/11/19 03:22:49 PM
#2029   Feel free to elaborate on the chart.......Where hedge_fun 01/11/19 11:05:04 AM
#2028   Don't know but the stock needs to move SidVicious 01/11/19 09:37:37 AM
#2027   Agreed!!! He's just trying to sell a product UKdude 01/11/19 09:27:59 AM
#2026   Clay is Captain Obvious who proves charting means SidVicious 01/11/19 08:47:21 AM
#2025   PRPO UP so far, 20% Pre-Market. Clay does instock58 01/11/19 07:50:58 AM
#2024   Now we are guaranteed a red Friday with SidVicious 01/10/19 10:31:55 PM
#2023   PRPO UP 45%, Up Another 11.72% After Hours instock58 01/10/19 05:17:11 PM
#2022   Took about a fifth of my position off PennyStockTrader2 01/10/19 05:07:40 PM
#2021   Nicely done. I held. I think it has mgland 01/10/19 04:48:10 PM
#2020   * * $PRPO Video Chart 01-10-19 * * ClayTrader 01/10/19 04:39:46 PM
#2019   Saw the news very early. In and aries4747 01/10/19 03:26:22 PM